Overview
- ATAGI’s 22 December advisory says Abhayrab doses given in India on or after 1 November 2023 should be considered potentially invalid, even though the product is not supplied in Australia.
- Guidance recommends repeat vaccination with Australia‑registered products such as Rabipur or Verorab plus antibody testing, with state public health units conducting follow‑up for known cases.
- Indian Immunologicals Limited disputes a blanket warning, asserting the problem involved a single counterfeit event tied to batch KA24014 identified in January 2025 and requesting ATAGI review its notice.
- The manufacturer says the suspect batch was removed from sale and emphasizes that government‑channel and authorised‑distributor supplies are tested and released by India’s Central Drugs Laboratory.
- Local probes reported fake vials in major hubs including Delhi, Mumbai, Ahmedabad and Lucknow, with entry points traced to wholesaler or grey‑market distribution, including a Delhi advisory issued on 23 March 2025.